Boehringer Technologies v. Tools For Surgery: Six-Patent Orogastric Tube Dispute Voluntarily Dismissed
Boehringer Technologies, LLC asserted six U.S. patents covering orogastric tube technology against Tools For Surgery, LLC in the Eastern District of Pennsylvania, targeting the Siren SGT and ZZIREN SGT tubes used in bariatric and gastric surgery. The case resolved by voluntary dismissal just 85 days after filing, before the defendant had answered or sought summary judgment.
Six-Patent Bariatric Surgery Tube Case Ends Before First Answer
On 25 June 2025, Boehringer Technologies, LLC — joined by affiliated entities Boehringer Laboratories, Inc. and Boehringer Laboratories, LLC — filed suit against Tools For Surgery, LLC in the U.S. District Court for the Eastern District of Pennsylvania (Case No. 2:25-cv-03229). The complaint asserted infringement of six U.S. patents directed to orogastric tube technology, specifically targeting defendant’s Siren SGT and ZZIREN SGT orogastric tubes marketed for bariatric and gastric surgical procedures.
Plaintiffs invoked Federal Rule of Civil Procedure 41(a)(1)(A)(i) to voluntarily dismiss the action on 18 September 2025, with each party bearing its own costs, expenses, and attorneys’ fees. That procedural vehicle — available only when no defendant has answered or moved for summary judgment — confirms the case concluded at the earliest possible stage of adversarial litigation. The public filing does not specify whether the dismissal was with or without prejudice, leaving the precise legal finality unconfirmed on the record.
An 85-day lifespan from filing to dismissal is notably compressed even by early-exit standards, and the absence of any defendant responsive pleading suggests the parties may have reached a private accommodation — or that plaintiff elected to withdraw before incurring further litigation expense. Without a court order specifying prejudice terms or a disclosed settlement agreement, the commercial resolution, if any, remains unknown from publicly available documents.
Filing to Voluntary dismissal in 85 days
85 days — resolved before defendant’s first responsive pleading
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): the earliest possible exit
Fed. R. Civ. P. 41(a)(1)(A)(i) permits a plaintiff to dismiss without a court order provided no defendant has answered or moved for summary judgment. That threshold was met here. This mechanism is self-executing — the case closes on filing of the notice alone. Critically, the notice here does not expressly state whether the dismissal is with or without prejudice, creating ambiguity about whether the claims can be refiled.
Pre-answer voluntary dismissalWith or without prejudice? The public record is silent
A Rule 41(a)(1) dismissal is without prejudice by default unless the notice states otherwise or a prior dismissal against the same defendant on the same claims triggers the ‘two-dismissal rule’ under Rule 41(a)(1)(B). The filed notice here specifies only that each party bears its own costs — it does not expressly characterise the dismissal as with or without prejudice. Until further action is taken publicly, the precise finality of these six patent claims against Tools For Surgery remains unclear.
Prejudice terms unconfirmedBoehringer retains enforcement flexibility — subject to Rule 41(a)(1)(B)
If the default without-prejudice interpretation applies, Boehringer Technologies and its affiliates retain the ability to reassert the six patents against Tools For Surgery in a future action. However, a second voluntary dismissal on the same claims against the same party would operate as an adjudication on the merits under the two-dismissal rule. Whether any private agreement constrains refiling is unknown from the public record.
Potential re-filing right retainedTools For Surgery exits without a merits ruling or admitted liability
Tools For Surgery never answered the complaint, meaning no admission of infringement, no invalidity finding, and no injunction were entered. The defendant also avoids a fee award. If the dismissal is effectively without prejudice, the Siren SGT and ZZIREN SGT products remain exposed to re-assertion of these six patents, suggesting defendant teams should monitor Boehringer’s IP activity closely going forward.
No liability admitted; exposure persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | BOEHRINGER TECHNOLOGIES, LLC | Company | Medical device IP portfolio company — holder of US10888446B2 and five further orogastric tube patentsSearch in Eureka ↗ |
| Defendant | TOOLS FOR SURGERY, LLC | Company | Surgical device company — maker of Siren SGT and ZZIREN SGT orogastric tubes for bariatric surgerySearch in Eureka ↗ |
| Plaintiff counsel | Manny D. Pokotilow. | Attorney | Counsel for BOEHRINGER TECHNOLOGIES, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Royer Cooper Cohen Braunfeld LLC | Law Firm | Representing BOEHRINGER TECHNOLOGIES, LLCSearch in Eureka ↗ |
| Presiding judge | Judge JOHN F MURPHY | Judge | Pennsylvania Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and records a mutual cost-bearing arrangement, but is silent on the prejudice characterisation. Under the Federal Rules, a first voluntary dismissal under this provision is presumed without prejudice, preserving plaintiff’s right to refile. No court order was entered, no merits were adjudicated, and no defendant liability was established. The cost-split term is consistent with either a clean walk-away or a privately settled dispute — the public record does not distinguish between these scenarios.
US10888446B2 and five further patents — orogastric tube technology for bariatric surgery
The six asserted patents — US10888446B2, US12303415B2, US9808368B2, US9999533B2, US11511030B2, and US10932937B2 — span application families filed between approximately 2013 and 2020, reflecting a sustained prosecution strategy across over a decade. Collectively, they are directed to orogastric tube technology used during bariatric and gastric surgical procedures, a specialised device category critical to sleeve gastrectomy and gastric bypass operations where accurate tube sizing directly affects surgical outcomes.
The breadth of this portfolio — six granted patents across at least four distinct application numbers — suggests Boehringer has constructed overlapping claim coverage designed to capture multiple design implementations of orogastric tube products. For competitors and device manufacturers active in the bariatric surgery segment, this portfolio represents a meaningful enforcement risk. The Siren SGT and ZZIREN SGT tubes named in the complaint indicate the patents cover commercially differentiated products, making FTO clearance for any new orogastric tube entrant commercially essential.
Should you run an FTO against the Boehringer orogastric tube patent portfolio?
Any medical device company developing, distributing, or rebranding orogastric tubes for bariatric or gastric surgery — including sleeve gastrectomy, gastric bypass, or revisional procedures — should treat this six-patent portfolio as a live enforcement risk. The pre-answer dismissal in this case does not extinguish the underlying IP; Boehringer retains granted rights across multiple patent families with staggered expiry dates. Surgical device distributors, OEM manufacturers, and bariatric surgery equipment importers operating in the U.S. market are the primary audience for this analysis.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of all six Boehringer patents, identify overlapping claim language across the portfolio families, and flag prior art that could inform invalidity arguments. Eureka’s citation graph and family tree tools allow R&D teams to identify design-around opportunities and monitor for continuation applications that may extend portfolio coverage. Run a portfolio-wide FTO — not just a single-patent check — given the layered filing strategy evident from this litigation.
Run a freedom-to-operate analysis on US10888446B2 to assess your product’s exposure
Run FTO in Eureka →Similar orogastric and bariatric surgical device patent cases in U.S. district courts
Explore related patent infringement actions involving orogastric tube, bariatric surgery device, and surgical equipment IP litigated in U.S. district courts.
What this case signals for the bariatric surgical device IP landscape
A six-patent complaint filed and withdrawn in 85 days, with costs split and no merits ruling, raises important questions for orogastric tube competitors.
Pre-answer dismissals often mask private resolutions — monitor both parties
When a plaintiff drops a multi-patent infringement case before the defendant even answers, it typically signals a negotiated outcome — licensing, design-around agreement, or commercial settlement — rather than a loss of confidence in the claims. IP teams tracking the bariatric device space should watch for licensing disclosures, product modifications, or new filings from Boehringer entities.
Six concurrent patents signal a defensive portfolio strategy worth mapping
Boehringer’s assertion of six patents across multiple application families for a single product category — orogastric tubes for bariatric surgery — suggests a layered filing strategy designed to create overlapping coverage. Competitors in the bariatric and gastric surgery device space should conduct FTO analysis across the full Boehringer portfolio, not just the patents named in this complaint.
BOEHRINGER v TOOLS — key questions answered
Boehringer Technologies asserted six U.S. patents: US10888446B2, US12303415B2, US9808368B2, US9999533B2, US11511030B2, and US10932937B2. All are directed to orogastric tube technology for bariatric and gastric surgery. The accused products were the Siren SGT and ZZIREN SGT orogastric tubes made by Tools For Surgery, LLC.
The plaintiffs filed a Rule 41(a)(1)(A)(i) notice of voluntary dismissal on 18 September 2025. The notice states each party bears its own costs, but does not specify whether the dismissal is with or without prejudice. No defendant answer or summary judgment motion had been filed, satisfying the procedural requirement for a unilateral dismissal. The commercial reason — settlement, licensing, or strategic withdrawal — is not disclosed in the public record.
The dismissal notice does not expressly state either characterisation. Under Fed. R. Civ. P. 41(a)(1), a first voluntary dismissal under this provision defaults to without prejudice unless specified otherwise. This means Boehringer and its affiliates may technically refile against Tools For Surgery on the same claims, though a second dismissal would trigger the two-dismissal rule and operate as an adjudication on the merits.
The complaint targeted the Siren SGT Orogastric Tubes and the ZZIREN SGT Orogastric Tubes, both made by Tools For Surgery, LLC and used in bariatric and gastric surgical procedures including sleeve gastrectomy and gastric bypass operations.
E.D. Pa. is not among the highest-volume patent litigation districts nationally, but it is a competent federal venue with experienced patent judges. Filing there — rather than in Delaware or W.D. Tex. — may reflect Boehringer’s operational or legal connections to the Pennsylvania region, or a strategic preference for local rules and docket management. The assignment to Judge John F. Murphy governed the case during its 85-day lifespan.
PatSnap Eureka searches patents and litigation data to answer instantly.